Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib

Cancer Research ◽

10.1158/0008-5472.can-21-0556 ◽

2021 ◽

pp. canres.0556.2021

Author(s):

Lei Zhu ◽

Zhen Chen ◽

Hongjing Zang ◽

Songqing Fan ◽

Jiajia Gu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Third Generation ◽

Egfr Tyrosine Kinase Inhibitor ◽

The Third ◽

Egfr Tyrosine Kinase ◽

Download Full-text

New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer

Annals of Oncology ◽

10.1093/annonc/mdz063.030 ◽

2019 ◽

Vol 30 ◽

pp. ii51

Author(s):

J. Fassunke ◽

C. Heydt ◽

S. Michels ◽

B. Van Veggel ◽

F. Müller ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Resistance Mechanisms ◽

Third Generation ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.05.024 ◽

2018 ◽

Vol 13 (9) ◽

pp. 1415-1421 ◽

Author(s):

Qi Zhang ◽

Xu-Chao Zhang ◽

Jin-Ji Yang ◽

Zhen-Fan Yang ◽

Yu Bai ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Third Generation ◽

Novel Mutations ◽

Egfr Tyrosine Kinase Inhibitor ◽

The Third ◽

Egfr Tyrosine Kinase

Download Full-text

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Download Full-text

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

Download Full-text

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Line Treatment ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

Breast Cancer Research and Treatment ◽

10.1007/s10549-007-9830-2 ◽

2007 ◽

Vol 112 (1) ◽

pp. 25-33 ◽

Author(s):

Nicola Normanno ◽

Manuela Campiglio ◽

Monica R. Maiello ◽

Antonella De Luca ◽

Mario Mancino ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Mapk Signaling ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

10.18632/oncotarget.7189 ◽

2016 ◽

Vol 7 (11) ◽

pp. 12404-12413 ◽

Author(s):

Shang-Gin Wu ◽

Yi-Nan Liu ◽

Meng-Feng Tsai ◽

Yih-Leong Chang ◽

Chong-Jen Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction

Tumor Biology ◽

10.1007/s13277-014-2932-7 ◽

2014 ◽

Vol 36 (4) ◽

pp. 2993-2999 ◽

Author(s):

Lixia Zhang ◽

Xiaokun Yang ◽

Bei Zhao ◽

Zhen Cai

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cell Carcinoma ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI

Annals of Oncology ◽

10.1093/annonc/mdx380.060 ◽

2017 ◽

Vol 28 ◽

pp. v485-v486 ◽

Author(s):

H. Husain ◽

R.G. Martins ◽

S.B. Goldberg ◽

P. Senico ◽

W. Ma ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Phase I Study ◽

Kinase Inhibitor ◽

Third Generation ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Mutant ◽

Download Full-text

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer

Molecular Medicine Reports ◽

10.3892/mmr.2020.11686 ◽

2020 ◽

Vol 23 (1) ◽

pp. 1-1

Author(s):

Yingjie Lu ◽

Dongliang Bian ◽

Xuelin Zhang ◽

Huibiao Zhang ◽

Zhenghong Zhu

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text